{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:07:28Z","timestamp":1790683648285,"version":"4.1.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2010,7,10]],"date-time":"2010-07-10T00:00:00Z","timestamp":1278720000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2010,7,10]],"date-time":"2010-07-10T00:00:00Z","timestamp":1278720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1007\/s10637-010-9488-1","type":"journal-article","created":{"date-parts":[[2010,7,9]],"date-time":"2010-07-09T03:19:32Z","timestamp":1278645572000},"page":"1406-1413","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Phase I study of weekly plitidepsin as 1-hour infusion combined with carboplatin in patients with advanced solid tumors or lymphomas"],"prefix":"10.1007","volume":"29","author":[{"given":"Ram\u00f3n","family":"Salazar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Plummer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Oaknin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Pardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arturo","family":"Soto-Matos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Yovine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Szyldergemajn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan Hilary","family":"Calvert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,7,10]]},"reference":[{"key":"9488_CR1","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/bjc.1998.570","volume":"78","author":"H Depenbrock","year":"1998","unstructured":"Depenbrock H, Peter R, Faircloth GT, Manzanares I, Jimeno J, Hanauske AR (1998) In vitro activity of aplidine, a new marine-derived anti-cancer compound, on freshly explanted clonogenic human tumour cells and haematopoietic precursor cells. Br J Cancer 78:739\u2013744","journal-title":"Br J Cancer"},{"key":"9488_CR2","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1038\/sj.cdd.4401898","volume":"13","author":"L Gonzalez-Santiago","year":"2006","unstructured":"Gonzalez-Santiago L, Suarez Y, Zarich N, Mu\u00f1oz-Alonso MJ, Cuadrado A, Martinez T, Goya L, Iradi A, Saez-Tormo G, Maier JV, Moorthy A, Cato AC, Rojas JM, Munoz A (2006) Aplidin induces JNK-dependent apoptosis in human breast cancer cells via alteration of glutathione homeostasis, Rac1 GTPase activation, and MKP-1 phosphatase downregulation. Cell Death Differ 13:1968\u20131981","journal-title":"Cell Death Differ"},{"key":"9488_CR3","doi-asserted-by":"publisher","first-page":"7533","DOI":"10.1038\/sj.onc.1205972","volume":"21","author":"LF Garcia-Fernandez","year":"2002","unstructured":"Garcia-Fernandez LF, Losada A, Alcaide V, Alvarez AM, Cuadrado A, Gonzalez L, Nakayama K, Nakayama KI, Fernandez-Sousa JM, Munoz A, Sanchez-Puelles JM (2002) Aplidin induces the mitochondrial apoptotic pathway via oxidative stress-mediated JNK and p38 activation and protein kinase C delta. Oncogene 21:7533\u20137544","journal-title":"Oncogene"},{"key":"9488_CR4","doi-asserted-by":"publisher","first-page":"4673","DOI":"10.1038\/sj.onc.1207636","volume":"23","author":"A Cuadrado","year":"2004","unstructured":"Cuadrado A, Gonzalez L, Suarez Y, Martinez T, Munoz A (2004) JNK activation is critical for Aplidin-induced apoptosis. Oncogene 23:4673\u20134680","journal-title":"Oncogene"},{"key":"9488_CR5","unstructured":"Mu\u00f1oz M, Alvarez E, Martinez T, Gonzalez-Santiago L, Sasak H, Lepage D, Aviles P, Mu\u00f1oz A (2007) JNK Activation as an In Vivo Marker of Aplidin\u00ae Activity. Proceedings AACR Annual Meeting:Abstract 5580"},{"key":"9488_CR6","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1093\/annonc\/mdi311","volume":"16","author":"M Biscardi","year":"2005","unstructured":"Biscardi M, Caporale R, Balestri F, Gavazzi S, Jimeno J, Grossi A (2005) VEGF inhibition and cytotoxic effect of aplidin in leukemia cell lines and cells from acute myeloid leukemia. Ann Oncol 16:1667\u20131674","journal-title":"Ann Oncol"},{"key":"9488_CR7","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1038\/sj.bjc.6601864","volume":"90","author":"G Taraboletti","year":"2004","unstructured":"Taraboletti G, Poli M, Dossi R, Manenti L, Borsotti P, Faircloth GT, Broggini M, D\u2019Incalci M, Ribatti D, Giavazzi R (2004) Antiangiogenic activity of aplidine, a new agent of marine origin. Br J Cancer 90:2418\u20132424","journal-title":"Br J Cancer"},{"key":"9488_CR8","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/sj.leu.2402788","volume":"17","author":"M Broggini","year":"2003","unstructured":"Broggini M, Marchini SV, Galliera E, Borsotti P, Taraboletti G, Erba E, Sironi M, Jimeno J, Faircloth GT, Giavazzi R, D\u2019Incalci M (2003) Aplidine, a new anticancer agent of marine origin, inhibits vascular endothelial growth factor (VEGF) secretion and blocks VEGF-VEGFR-1 (flt-1) autocrine loop in human leukemia cells MOLT-4. Leukemia 17:52\u201359","journal-title":"Leukemia"},{"key":"9488_CR9","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s00280-005-0014-7","volume":"57","author":"AM Straight","year":"2006","unstructured":"Straight AM, Oakley K, Moores R, Bauer AJ, Patel A, Tuttle RM, Jimeno J, Francis GL (2006) Aplidin reduces growth of anaplastic thyroid cancer xenografts and the expression of several angiogenic genes. Cancer Chemother Pharmacol 57:7\u201314","journal-title":"Cancer Chemother Pharmacol"},{"key":"9488_CR10","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.critrevonc.2007.02.001","volume":"63","author":"DJ Stewart","year":"2007","unstructured":"Stewart DJ (2007) Mechanisms of resistance to cisplatin and carboplatin. Crit Rev Oncol Hematol 63:12\u201331","journal-title":"Crit Rev Oncol Hematol"},{"key":"9488_CR11","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1074\/jbc.M201010200","volume":"278","author":"A Cuadrado","year":"2003","unstructured":"Cuadrado A, Garcia-Fernandez LF, Gonzalez L, Suarez Y, Losada A, Alcaide V, Martinez T, Fernandez-Sousa JM, Sanchez-Puelles JM, Munoz A (2003) Aplidin induces apoptosis in human cancer cells via glutathione depletion and sustained activation of the epidermal growth factor receptor, Src, JNK, and p38 MAPK. J Biol Chem 278:241\u2013250","journal-title":"J Biol Chem"},{"key":"9488_CR12","unstructured":"Anthoney A, Paz-Ares L, Twelves C, Cortes-Funes H, Kaye S, Pronk L, Celli N, Lopez-Lazaro L, Guzman C, Jimeno J (2000) Phase I and pharmacokinetic (PK) study of Aplidin (APL) using a 24-hour, weekly schedule. Proc Am Soc Clin Oncol 19:Abstract 734"},{"key":"9488_CR13","first-page":"422","volume":"21","author":"EM Ciruelos","year":"2002","unstructured":"Ciruelos EM, Twelves C, Dominguez MJ, Mckay H, Anthony A, Castellanos D, Bezares S, Ruiz A, Lopez-Lazaro L, Jimeno J, Celli C, Cortes-Funes H, Paz-Ares L (2002) Phase I clinical and pharmacokinetic study of the marine compound Aplidin (APL) administered as a 3\u00a0h infusion every 2\u00a0weeks. Proc Am Soc Clin Oncol 21:Abstract 422","journal-title":"Proc Am Soc Clin Oncol"},{"key":"9488_CR14","unstructured":"Bowman A, Izquierdo MA, Jodrell D, Martinez M, Cicchella B, Jimeno J, Guzman C, Germa-Lluch J, Celli N, Smyth J (2001) Phase I clinical and pharmacokinetic (PK) study of the marine compound Aplidin (APL), administered as a 1\u00a0h weekly infusion. Proc Am Soc Clin Oncol 20:Abstract 476"},{"key":"9488_CR15","doi-asserted-by":"publisher","first-page":"7780","DOI":"10.1200\/JCO.2005.08.004","volume":"23","author":"S Faivre","year":"2005","unstructured":"Faivre S, Chieze S, Delbaldo C, Ady-Vago N, Guzman C, Lopez-Lazaro L, Lozahic S, Jimeno J, Pico F, Armand JP, Martin JA, Raymond E (2005) Phase I and pharmacokinetic study of aplidine, a new marine cyclodepsipeptide in patients with advanced malignancies. J Clin Oncol 23:7780\u20137782","journal-title":"J Clin Oncol"},{"key":"9488_CR16","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1093\/annonc\/mdl165","volume":"17","author":"JA Maroun","year":"2006","unstructured":"Maroun JA, Belanger K, Seymour L, Matthews S, Roach J, Dionne J, Soulieres D, Stewart D, Goel R, Charpentier D, Goss G, Tomiak E, Yau J, Jimeno J, Chiritescu G (2006) Phase I study of Aplidine in a dailyx5 one-hour infusion every 3\u00a0weeks in patients with solid tumors refractory to standard therapy. A National Cancer Institute of Canada Clinical Trials Group study: NCIC CTG IND 115. Ann Oncol 17:1371\u20131378","journal-title":"Ann Oncol"},{"key":"9488_CR17","volume-title":"Cancer chemotherapy and biotherapy: principles and practice","author":"B Chabner","year":"2006","unstructured":"Chabner B, Longo DL (2006) Cancer chemotherapy and biotherapy: principles and practice, 4th edn. Lippincott Williams & Wilkins, Philadelphia","edition":"4"},{"key":"9488_CR18","doi-asserted-by":"publisher","first-page":"3105","DOI":"10.1158\/1078-0432.CCR-07-1652","volume":"14","author":"MA Izquierdo","year":"2008","unstructured":"Izquierdo MA, Bowman A, Garcia M, Jodrell D, Martinez M, Pardo B, Gomez J, Lopez-Martin JA, Jimeno J, Germa JR, Smyth JF (2008) Phase I clinical and pharmacokinetic study of plitidepsin as a 1-hour weekly intravenous infusion in patients with advanced solid tumors. Clin Cancer Res 14:3105\u20133112","journal-title":"Clin Cancer Res"},{"key":"9488_CR19","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.1989.7.11.1748","volume":"7","author":"AH Calvert","year":"1989","unstructured":"Calvert AH, Newell DR, Gumbrell LA, O\u2019Reilly S, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME, Wiltshaw E (1989) Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7:1748\u20131756","journal-title":"J Clin Oncol"},{"key":"9488_CR20","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205\u2013216","journal-title":"J Natl Cancer Inst"},{"key":"9488_CR21","doi-asserted-by":"crossref","first-page":"3558","DOI":"10.1200\/JCO.2000.18.20.3558","volume":"18","author":"H Ozer","year":"2000","unstructured":"Ozer H, Armitage JO, Bennett CL, Crawford J, Demetri GD, Pizzo PA, Schiffer CA, Smith TJ, Somlo G, Wade JC, Wade JL 3rd, Winn RJ, Wozniak AJ, Somerfield MR (2000) 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol 18:3558\u20133585","journal-title":"J Clin Oncol"},{"key":"9488_CR22","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1182\/blood-2002-06-1767","volume":"100","author":"JD Rizzo","year":"2002","unstructured":"Rizzo JD, Lichtin AE, Woolf SH, Seidenfeld J, Bennett CL, Cella D, Djulbegovic B, Goode MJ, Jakubowski AA, Lee SJ, Miller CB, Rarick MU, Regan DH, Browman GP, Gordon MS (2002) Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Blood 100:2303\u20132320","journal-title":"Blood"},{"key":"9488_CR23","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1158\/1078-0432.284.11.1","volume":"11","author":"WK Oh","year":"2005","unstructured":"Oh WK, Hagmann E, Manola J, George DJ, Gilligan TD, Jacobson JO, Smith MR, Kaufman DS, Kantoff PW (2005) A phase I study of estramustine, weekly docetaxel, and carboplatin chemotherapy in patients with hormone-refractory prostate cancer. Clin Cancer Res 11:284\u2013289","journal-title":"Clin Cancer Res"},{"key":"9488_CR24","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1002\/cncr.21287","volume":"104","author":"K Yonemori","year":"2005","unstructured":"Yonemori K, Katsumata N, Yamamoto N, Kasamatsu T, Yamada T, Tsunematsu R, Fujiwara Y (2005) A phase I study and pharmacologic evaluation of irinotecan and carboplatin for patients with advanced ovarian carcinoma who previously received platinum-containing chemotherapy. Cancer 104:1204\u20131212","journal-title":"Cancer"},{"key":"9488_CR25","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s00280-006-0188-7","volume":"58","author":"M Fukuda","year":"2006","unstructured":"Fukuda M, Soda H, Soejima Y, Kinoshita A, Takatani H, Kasai T, Nagashima S, Kawabata S, Doi S, Kohno S, Oka M (2006) A phase I trial of carboplatin and etoposide for elderly (>or=75 year-old) patients with small-cell lung cancer. Cancer Chemother Pharmacol 58:601\u2013606","journal-title":"Cancer Chemother Pharmacol"},{"key":"9488_CR26","doi-asserted-by":"publisher","first-page":"4603","DOI":"10.1200\/JCO.2007.10.8688","volume":"25","author":"K Appleton","year":"2007","unstructured":"Appleton K, Mackay HJ, Judson I, Plumb JA, McCormick C, Strathdee G, Lee C, Barrett S, Reade S, Jadayel D, Tang A, Bellenger K, Mackay L, Setanoians A, Schatzlein A, Twelves C, Kaye SB, Brown R (2007) Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors. J Clin Oncol 25:4603\u20134609","journal-title":"J Clin Oncol"},{"key":"9488_CR27","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1097\/01.coc.0000242292.17728.46","volume":"30","author":"K Kaira","year":"2007","unstructured":"Kaira K, Tsuchiya S, Sunaga N, Yanagitani N, Watanabe S, Imai H, Hisada T, Ishizuka T, Saito R, Mori M (2007) A phase I dose escalation study of weekly docetaxel and carboplatin in elderly patients with nonsmall cell lung cancer. Am J Clin Oncol 30:51\u201356","journal-title":"Am J Clin Oncol"},{"key":"9488_CR28","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1007\/s00280-007-0423-x","volume":"60","author":"TE Stinchcombe","year":"2007","unstructured":"Stinchcombe TE, Socinski MA, Walko CM, O\u2019Neil BH, Collichio FA, Ivanova A, Mu H, Hawkins MJ, Goldberg RM, Lindley C, Claire Dees E (2007) Phase I and pharmacokinetic trial of carboplatin and albumin-bound paclitaxel, ABI-007 (Abraxane) on three treatment schedules in patients with solid tumors. Cancer Chemother Pharmacol 60:759\u2013766","journal-title":"Cancer Chemother Pharmacol"},{"key":"9488_CR29","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.ygyno.2007.08.071","volume":"108","author":"PT Ramirez","year":"2008","unstructured":"Ramirez PT, Landen CN Jr, Coleman RL, Milam MR, Levenback C, Johnston TA, Gershenson DM (2008) Phase I trial of the proteasome inhibitor bortezomib in combination with carboplatin in patients with platinum- and taxane-resistant ovarian cancer. Gynecol Oncol 108:68\u201371","journal-title":"Gynecol Oncol"},{"key":"9488_CR30","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3390\/md7010057","volume":"7","author":"P Sch\u00f6ffski","year":"2009","unstructured":"Sch\u00f6ffski P, Guillem V, Garcia M, Rivera F, Tabernero J, Cullell M, Lopez-Martin JA, Pollard P, Dumez H, Garcia del Muro X, Paz-Ares L (2009) Phase II randomized study of plitidepsin (Aplidin), alone or in association with L-carnitine, in patients with unresectable advanced renal cell carcinoma. Mar Drugs 7:57\u201370","journal-title":"Mar Drugs"},{"key":"9488_CR31","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.lungcan.2008.06.017","volume":"64","author":"T Eisen","year":"2009","unstructured":"Eisen T, Thatcher N, Leyvraz S, Miller WH Jr, Couture F, Lorigan P, Luthi F, Small D, Tanovic A, O\u2019Brien M (2009) Phase II study of weekly plitidepsin as second-line therapy for small cell lung cancer. Lung Cancer 64:60\u201365","journal-title":"Lung Cancer"},{"key":"9488_CR32","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.lungcan.2007.10.019","volume":"60","author":"C Peschel","year":"2008","unstructured":"Peschel C, Hartmann JT, Schmittel A, Bokemeyer C, Schneller F, Keilholz U, Buchheidt D, Millan S, Izquierdo MA, Hofheinz RD (2008) Phase II study of plitidepsin in pretreated patients with locally advanced or metastatic non-small cell lung cancer. Lung Cancer 60:374\u2013380","journal-title":"Lung Cancer"},{"key":"9488_CR33","first-page":"320","volume":"10","author":"C Baylis","year":"1990","unstructured":"Baylis C, Handa RK, Sorkin M (1990) Glucocorticoids and control of glomerular filtration rate. Semin Nephrol 10:320\u2013329","journal-title":"Semin Nephrol"},{"key":"9488_CR34","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ctrv.2006.09.006","volume":"33","author":"CA Rabik","year":"2007","unstructured":"Rabik CA, Dolan ME (2007) Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 33:9\u201323","journal-title":"Cancer Treat Rev"},{"key":"9488_CR35","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/BF00194562","volume":"9","author":"DD Von Hoff","year":"1991","unstructured":"Von Hoff DD, Turner J (1991) Response rates, duration of response, and dose response effects in phase I studies of antineoplastics. Invest New Drugs 9:115\u2013122","journal-title":"Invest New Drugs"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-010-9488-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-010-9488-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-010-9488-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-010-9488-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T05:04:06Z","timestamp":1678511046000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-010-9488-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7,10]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["9488"],"URL":"https:\/\/doi.org\/10.1007\/s10637-010-9488-1","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,7,10]]},"assertion":[{"value":"26 May 2010","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2010","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2010","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}